Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.
Pitocco, D., Tartaglione, L., Viti, L., Di Leo, M., Pontecorvi, A., Caputo, S., SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?, <<DIABETES RESEARCH AND CLINICAL PRACTICE>>, 2020; 163 (N/A): 1-3. [doi:10.1016/j.diabres.2020.108162] [https://hdl.handle.net/10807/221587]
SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
Pitocco, Dario;Tartaglione, Linda;Viti, Luca;Di Leo, Mauro;Pontecorvi, Alfredo;Caputo, Salvatore
2020
Abstract
Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
